Scientists investigate genetics of HIV-1 resistance

October 26, 2012
Scientists investigate genetics of HIV-1 resistance
Credit: Shutterstock

Investigating the genetic footprint that drug resistance causes in HIV, researchers in Europe have discovered that compensatory polymorphisms enable resistant viruses to survive. Presented in the journal Retrovirology, the study was supported in part by three EU-funded projects: VIROLAB, EURESIST and CHAIN.

Both the VIROLAB ('A for decision support in treatment') and EURESIST ('Integration of viral genomics with clinical data to predict response to anti-') projects were funded under the 'Information society technologies' (IST) Thematic area of the EU's Sixth Framework Programme (FP6) to the tune of EUR 3.3 million and EUR 2.1 million, respectively. CHAIN ('Collaborative HIV and anti- network') has received almost EUR 10 million under the Health Theme of the EU's Seventh Framework Programme (FP7).

Preventing viral replication is the current mode of HIV-1 infection treatment. Researchers measure the number of viral particles in the blood and analyse the cluster of differentiation 4 (CD4) count to repair the immune system. Since the early 1990s, the research world has seen a marked improvement in the treatment and life expectancy of HIV patients. But drug resistance has forced researchers and physicians to come up with an array of drugs to obtain complete .

According to the researchers, virus drug resistance comes at a cost. The virus carrying is less 'fit' than the wild-type virus when the drug is not present. Because of this, replication should be no simple task. During interruptions to treatment, wild-type viruses quickly predominate. But newly infected people can be drug resistant even before treatment begins for them.

The SPREAD project researchers monitored HIV infections across Europe, assessing 1 600 individuals who were newly infected with HIV-1 subtype B. They found that HIV-1 harboured transmitted (TDR) in 10 % of the subjects. The team measured virus production and CD4 count, observing there was no indication that these strains of HIV-1 were weaker.

Recent studies have put the spotlight on polymorphisms, naturally occurring differences in the genes that lead to differences between animals of the same species, including blood groups. They may also increase propensity for certain diseases like cancer and type 2 diabetes. However, viruses also harbour polymorphisms.

In this study, the team discovered that polymorphisms in these strains of HIV-1, specific polymorphisms in the gene coding for protease, which is needed for viral replication, and known to act as compensatory mechanisms, make resistant strains 'fitter', even in the absence of the drug. 'Our worry is that over time we will be seeing more people presenting with TDR HIV-1,' said lead author Kristof Theys of the University of Leuven in Belgium.

Senior author Professor Anne-Mieke Vandamme, also from the University of Leuven, said: 'Contrary to what was expected, transmission of TDR virus may also contribute to a "fitter" and more virulent HIV, which has important clinical implications in how we best treat these people.'

Explore further: The genetics of HIV-1 resistance

Related Stories

The genetics of HIV-1 resistance

October 2, 2012
Drug resistance is a major problem when treating infections. This problem is multiplied when the infection, like HIV-1, is chronic. New research published in BioMed Central's open access journal Retrovirology has examined ...

Drug designer: New tool reveals mutations that cause HIV-drug resistance

July 8, 2011
Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new ...

Recommended for you

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017
A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.

HIV-AIDS: Following your gut

September 18, 2017
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have discovered a way to slow viral replication in the gastrointestinal tract of people infected by HIV-AIDS.

Study finds cutbacks in foreign aid for HIV treatment would cause great harm

August 30, 2017
Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports. In their paper published online ...

Cancer drug can reactivate HIV

August 24, 2017
People living with HIV must take a combination of three or more different drugs every day for the rest of their lives. Unfortunately, by following this strict treatment plan, they can suffer from side effects ranging from ...

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.